[12th Post-ECTRIMS Meeting: review of the novelties from the 2019 ECTRIMS Congress (I)].

Introduction: Like every year, after the ECTRIMS Congress, renowned Spanish neurologists who are experts in multiple sclerosis presented the main novelties in research in this field at the Post-ECTRIMS Meeting.

Aim: To summarise the content presented at the 12th edition of the Post-ECTRIMS Meeting, which took place in September 2019 in Sevilla and is presented in two parts.

Development: This first part addresses the latest studies on vitamin D deficiency and the discrepancies that currently exist regarding its treatment.

Review of the novelties presented at the 2018 ECTRIMS Congress: 11th Post-ECTRIMS Meeting (II).

The Post-ECTRIMS Meeting was held for the eleventh consecutive year in October 2018 in Madrid, with the aim of analysing the advances made in multiple sclerosis that were highlighted at the latest ECTRIMS annual congress. Based on the issues discussed at this meeting, attended by the nation's foremost opinion leaders on multiple sclerosis, two review articles are presented. This second part includes the growing body of evidence confirming the safety of exposure to disease-modifying treatments in women planning a pregnancy, and the beneficial effect of breastfeeding, provided that the disease is not very active.

[Review of the novelties presented at the 2018 ECTRIMS Congress: 11th Post-ECTRIMS Meeting (I)].

The Post-ECTRIMS Meeting is an emblematic event in Spain which seeks to review and disseminate the main advances in multiple sclerosis presented at the ECTRIMS annual congress. In October 2018, the eleventh Post-ECTRIMS meeting was held in Madrid and was attended by the country's leading experts in multiple sclerosis. As a result of this meeting, we present two articles which outline the most interesting novelties discussed there.

Once-daily LCP-Tacro MeltDose tacrolimus for the prophylaxis of organ rejection in kidney and liver transplantations.

Tacrolimus is a cornerstone of the immunosuppression regimen for prevention of allograft rejection in kidney and liver transplantations, with efficacy proven in many clinical trials. The currently available and extensively used tacrolimus formulations are flawed by large inter- and intra-individual variability, low bioavailability, wide peak-to-trough fluctuations and a narrow therapeutic index. Drug delivery technology can significantly impact the pharmacologic action of a drug, influencing its pharmacokinetic and subsequent therapeutic profile.

Cervical and anal HPV infections in HIV positive women and men.

The goal of this review is to summarize recently published epidemiological information that contribute to understanding the natural history of cervical and human papillomavirus (HPV) infection and their associated lesions among human immunodeficiency virus (HIV) infected women and men. HIV-positive women and men are more likely to be infected with oncogenic HPV types and to have cervical intraepithelial neoplasia (CIN) or anal intraepithelial neoplasia (AIN), lesions that may lead to invasive cervical and anal cancer, respectively. Although the magnitude of the increased risk of cervical or anal cancer in HIV-positive individuals is not clear, it is clear that the risk will remain elevated even in the HAART era.